British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010.

British HIV Association (BHIVA), BHIVA Secretariat, Mediscript Ltd, London, UK.
HIV Medicine (Impact Factor: 3.45). 11/2010; 11(10):611-9. DOI: 10.1111/j.1468-1293.2010.00889.x
Source: PubMed
Download full-text


Available from: Jane Anderson, Nov 02, 2014
  • Source
    HIV Testing, 01/2012; , ISBN: 978-953-307-871-7
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Infection with human immunodeficiency virus type 2 (HIV-2) occurs mainly in West Africa, but an increasing number of cases have been recognized in Europe, India, and the United States. In this era of global integration, clinicians must be aware of when to consider the diagnosis of HIV-2 infection and how to test for this virus. Although there is debate regarding when therapy should be initiated and which regimen should be chosen, recent trials have provided important information on treatment options for HIV-2 infection. In this review, we present information on recent clinical advances in our understanding of HIV-2 infection and highlight remaining diagnostic and therapeutic challenges.
    Clinical Infectious Diseases 03/2011; 52(6):780-7. DOI:10.1093/cid/ciq248 · 9.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: HIV-2 is responsible for a limited epidemic in West Africa. Around 20% of all infected patients will progress to AIDS, and will need antiretroviral therapy. Unfortunately, antiretrovirals were developed to suppress HIV-1 replication; not all of them are active against HIV-2, e.g. all nonnucleoside reverse transcriptase inhibitors or fusion inhibitors. Moreover, only three protease inhibitors have the same activity in HIV-1 and HIV-2: lopinavir, saquinavir and darunavir. Even if all nucleoside and nucleotide reverse transcriptase inhibitors appear to be equally efficient against HIV-2, different resistance pathways and an increased facility of resistance selection make their use much more difficult than in HIV-1. Integrase inhibitors have a potent inhibitory effect on HIV-2 replication, but questions about the best timing for their use remain unanswered, as well as those regarding the use of entry inhibitors in this setting. The lack of reliable monitoring tools adds to the difficulty of treating HIV-2-infected patients, mostly because the viral load is not as useful as it is in HIV-1, and the incomplete knowledge about resistance pathways limits the clinical usefulness of resistance testing. With all these limitations, HIV-2 treatment remains a challenge. Further research is urgently needed, since antiretroviral therapy is now becoming available in countries where the HIV-2 prevalence is significant. The need for appropriate guidelines for HIV-2 treatment has become an emergency.
    Intervirology 01/2012; 55(2):179-83. DOI:10.1159/000332025 · 1.77 Impact Factor